Primaquine Dosing in G6PD Deficiency for P. vivax
For patients with confirmed G6PD deficiency and P. vivax malaria, use weekly primaquine at 0.75 mg/kg (maximum 45 mg) once weekly for 8 weeks, but ONLY if the patient has intermediate G6PD deficiency (30-70% activity) with the African A- variant—avoid primaquine entirely in severe G6PD deficiency (<30% activity) or Mediterranean B- variant. 1, 2
Critical G6PD Variant Distinction
The management hinges on two key factors: the degree of G6PD deficiency and the specific genetic variant:
- African A- variant with intermediate deficiency (30-70% activity): Relatively resistant to severe primaquine-induced hemolysis; weekly dosing is feasible 1
- Mediterranean B- variant: Very high risk of severe hemolysis even with extended dosing regimens—primaquine is contraindicated 1
- Severe deficiency (<30% activity): Primaquine is absolutely contraindicated regardless of variant 2
Specific Dosing Algorithm
For Intermediate G6PD Deficiency (30-70% activity), Non-Mediterranean Variant:
- Dose: 0.75 mg base/kg once weekly (maximum 45 mg)
- Duration: 8 weeks
- Monitoring: Close hematological monitoring required throughout treatment 1
For Severe G6PD Deficiency (<30% activity) or Mediterranean Variant:
- Do NOT use primaquine 1, 2
- Treat blood-stage infection only with chloroquine or artemisinin-based combination therapy
- Accept risk of relapse or use suppressive therapy during high-risk periods
Essential Safety Monitoring
Before initiating any primaquine regimen in G6PD deficiency:
- Baseline testing: Check hematocrit and hemoglobin before treatment 2
- Early monitoring: Repeat hemoglobin on days 3 and 8 2
- Adequate medical support must be available to manage potential hemolytic crisis 2
- Discontinue immediately if signs of hemolysis appear (darkening urine, marked hemoglobin drop) 2
Evidence Quality and Nuances
The 2024 Clinical Microbiology and Infection guidelines 1 provide the most current framework, explicitly distinguishing between G6PD variants. Research data from 3 supports the safety of weekly primaquine (PQ8W) across various G6PD variants, showing only a 5.1% 12-month recurrence risk and good tolerability in most patients, though two hemizygous males experienced significant hemoglobin drops requiring monitoring.
Critical pitfall: The FDA label 2 states primaquine "should not be prescribed for patients with severe G6PD deficiency" but allows consideration for mild-to-moderate deficiency with risk-benefit assessment. However, the guideline evidence 1 is more specific—only the African A- variant with intermediate activity should receive weekly primaquine, not all "mild-to-moderate" deficiency.
Alternative Approach: Tafenoquine
Tafenoquine is contraindicated if G6PD activity is <70%, making it unsuitable for most G6PD-deficient patients 1. It is not an option for this population.
Pregnancy Consideration
Primaquine is absolutely contraindicated in pregnancy regardless of maternal G6PD status, as the fetal G6PD status is unknown 2, 4. Use suppressive chloroquine or hydroxychloroquine therapy during pregnancy instead.